<DOC>
	<DOCNO>NCT02965846</DOCNO>
	<brief_summary>The objective study twofold •To evaluate safety efficacy 0.1 % AGN-195263 administer twice daily compare vehicle patient evaporative dry eye ( EDE ) •To evaluate systemic pharmacokinetics 0.1 % AGN-195263 administer twice daily patient EDE</brief_summary>
	<brief_title>Topical Ophthalmic AGN-195263 Treatment Evaporative Dry Eye</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<criteria>Male , 18 year age old , screen ( day 51 ) visit OR Females , naturally postmenopausal ( permanent cessation menstrual period least 12 consecutive month ) permanently sterilize ( ie , eg , tubal occlusion , hysterectomy , bilateral salpingectomy , and/or bilateral oophorectomy ) screening ( day 51 ) visit In least 1 eye , follow objective measure evaporative dry eye ( EDE ) must present standardization ( day 21 ) baseline ( day 1 ) visit . The eye must qualify visit Tear film breakup time ( TBUT ) ≥ 2 second ≤ 7 second Corneal sodium fluorescein stain score ≥ 1 ≤ 4 ( Oxford scheme ) Anesthetized Schirmer 's tear test score ≥ 10 mm 5 minute At standardization ( day 21 ) baseline ( day 1 ) visit , patient must : Ocular Surface Disease Index© ( OSDI ) score &gt; 12 ( 0 100 scale ) Overall ocular discomfort score ≥ 1 &lt; 4 ( 0 4 scale ; 0 = none , 4 = severe ) Ocular burn score ≥ 1 &lt; 4 ( 0 4 scale ; 0 = none , 4 = severe ) Blurred vision score ≥ 1 &lt; 4 ( 0 4 scale ; 0 = none , 4 = severe ) In least 1 eye , low lid margin meibum quality global assessment score ≥ 1 standardization ( day 21 ) baseline ( day 1 ) visit . The eye must qualify visit In least 1 eye , number lower lid margin expressible meibomian gland must ≥ 3 standardization ( day 21 ) baseline ( day 1 ) visit . The eye must qualify visit Use artificial tear product , lid hygiene ( ie , warm compress , lid massage , lid scrub ) , omega3 supplementation ( topical ocular systemic ) , antibiotic ( ie , systemic topical macrolides , tetracycline , tetracycline derivative [ include doxycycline minocycline ] ) treatment dry eye disease , meibomian gland disease within 1 year standardization ( day 21 ) visit Male patient history , know , suspected prostate cancer Male patient prostatespecific antigen ( PSA ) level ≥ 4 μg/L Female patient history know suspect breast , cervical , ovarian , uterine cancer Female patient childbearing potential At standardization ( day 21 ) / baseline ( day 1 ) visit , low lid margin meibum quality global assessment score nonexpressible ( NE ) either eye Patients currently use estrogen and/or progesterone containing product ( include herbal nutritional supplement ) stable dose ( least 90 day prior standardization visit ( day 21 ) and/or anticipate initiating use and/or change use study Patients currently use use androgen antiandrogen treatment ( include herbal nutritional supplement ) , within 90 day standardization ( day 21 ) visit anticipate use study Patients currently use use hair growth product within 90 day standardization ( day 21 ) visit anticipate use study Patients currently use use topical corticosteroid eye eyelid within 60 day prior standardization visit ( day 21 ) , use anticipated prior month 6 visit Patients currently use use oral topical macrolides , tetracycline , tetracycline derivative drug ( include doxycycline minocycline ) , retinoids ( eg , isotretinoin ) , calcineurin inhibitor ( ie , RESTASIS® , Ikervis® ) , oral ( systemic ) corticosteroid , lifitegrast ( Xiidra™ ) therapeutic dry eye treatment within 60 day standardization visit ( day 21 ) , anticipate use month 6 visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>EDE</keyword>
	<keyword>evaporative dry eye</keyword>
</DOC>